{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+CLL&page=7",
    "query": {
      "condition": "Relapsed CLL",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 674,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+CLL&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+CLL&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T16:25:17.977Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06542250",
      "title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Malignancies"
      ],
      "interventions": [
        {
          "name": "AZD5492",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2024-09-18",
      "completion_date": "2029-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06542250"
    },
    {
      "nct_id": "NCT02756897",
      "title": "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2016-07-07",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02756897"
    },
    {
      "nct_id": "NCT03524235",
      "title": "Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "CLL",
        "Chronic Lymphocytic Leukemia",
        "Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Haploidentical Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "CD56-Enriched Donor Lymphocyte Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Noah Merin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-07-18",
      "completion_date": "2024-11-06",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03524235"
    },
    {
      "nct_id": "NCT01885897",
      "title": "IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myelodysplastic Syndromes (MDS)",
        "Lymphoma",
        "Myeloma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chronic Myelogenous Leukemia (CML)"
      ],
      "interventions": [
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-11-11",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885897"
    },
    {
      "nct_id": "NCT00003962",
      "title": "Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-04",
      "completion_date": "2000-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003962"
    },
    {
      "nct_id": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "clofarabine",
          "type": "DRUG"
        },
        {
          "name": "stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2008-01",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617929"
    },
    {
      "nct_id": "NCT01699152",
      "title": "Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "TG02 citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tragara Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-09",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2019-07-25",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 5,
      "location_summary": "Augusta, Georgia • Boston, Massachusetts • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01699152"
    },
    {
      "nct_id": "NCT01682616",
      "title": "A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Lymphocytic Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "ABT-199",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 49,
      "start_date": "2012-07-25",
      "completion_date": "2022-06-23",
      "has_results": false,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 4,
      "location_summary": "La Jolla, California • Chicago, Illinois • New Hyde Park, New York + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682616"
    },
    {
      "nct_id": "NCT00134017",
      "title": "Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Months to 65 Years"
      },
      "enrollment_count": 142,
      "start_date": "2004-06",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134017"
    },
    {
      "nct_id": "NCT00193518",
      "title": "Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Arsenic Trioxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2004-04",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2011-05-03",
      "last_synced_at": "2026-10-30T16:25:17.977Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00193518"
    }
  ]
}